Elena Dubcenco

P189 Efficacy and safety of upadacitinib maintenance treatment in patients with moderately to severely active crohn’s disease: 3-year results from U-ENDURE

Edward V Loftus, Geert R D’Haens, Edouard Louis, Miguel D Regueiro et autres

us, nl, be, ca, pt, jp, gb, de (code pays fourni par la source)

Tu1645 EFFICACY AND SAFETY OF UPADACITINIB AFTER 5 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM ANALYSIS FROM THE PHASE 3 UACTIVATE OPEN-LABEL EXTENSION STUDY

Remo Panaccione, Jean Frédéric Colombel, Hiroshi Nakase, Elena Dubcenco et autres

Tu1644 LONG-TERM EFFICACY OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE AND PRIOR BIOLOGIC USE

Raja Atreya, Remo Panaccione, Edouard Louis, David T. Rubin et autres

Tu1645 EFFICACY AND SAFETY OF UPADACITINIB AFTER 5 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM ANALYSIS FROM THE PHASE 3 UACTIVATE OPEN-LABEL EXTENSION STUDY

Remo Panaccione, Jean Frédéric Colombel, Hiroshi Nakase, Elena Dubcenco et autres

Tu1644 LONG-TERM EFFICACY OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE AND PRIOR BIOLOGIC USE

Raja Atreya, Remo Panaccione, Edouard Louis, David T. Rubin et autres

Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies

Remo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel et autres

BACKGROUND & AIMS: Upadacitinib (UPA) is an oral, reversible Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We assessed the long-term safety of UPA in both inflammatory bowel disease (IBD) entities. METHODS: Safety from 6 …

ca, es, fr, us, gb, be, de (code pays fourni par la source)

P1108 Upadacitinib improves histologic and endoscopic-histologic outcomes in the colon and ileum of patients with moderately to severely active Crohn’s disease

F Magro, V Jairath, L Peyrin-Biroulet, S van Haaren et autres

Abstract Background In addition to endoscopic evaluation, histologic assessment of mucosal healing in patients with Crohn’s disease (CD) may provide further insights into the inflammatory status of their disease. Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for the treatment of …

pt, ca, fr, us (code pays fourni par la source)

DOP056 Efficacy and Safety of Upadacitinib After 5 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Analysis From the Phase 3 U-ACTIVATE Open-Label Extension Study

R Panaccione, J F Colombel, H Nakase, Elena Dubcenco et autres

Abstract Background Clinical remission and endoscopic healing are long-term treatment targets for ulcerative colitis (UC).1 U-ACTIVATE is an ongoing phase 3 long-term extension (LTE) study evaluating the efficacy and safety of upadacitinib (UPA),2 an oral, selective Janus kinase inhibitor approved for adults …

ca, us, jp (code pays fourni par la source)

P0895 Long-Term Efficacy of Upadacitinib in Patients With Moderate-to-Severe Crohn’s Disease and Prior Biologic Use

Raja Atreya, R Panaccione, E Louis, D T Rubin et autres

Abstract Background The long-term efficacy and safety of the selective JAK inhibitor upadacitinib (UPA) in patients with moderate-to-severe Crohn’s disease (CD) are currently being evaluated in the ongoing U-ENDURE long-term extension (LTE) study.1 Here, we report the efficacy of 2 years of …

de, ca, be, us, fr (code pays fourni par la source)

P0774 Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

J Panés, E Louis, P Bossuyt, Namita Joshi et autres

Abstract Background Health-related quality of life (HRQoL) is impaired in patients with Crohn’s disease (CD). Upadacitinib (UPA), a Janus kinase inhibitor, demonstrated efficacy and safety in the phase 3 U-EXCEED (NCT03345836) and U-EXCEL (NCT03345849) induction, and U-ENDURE (NCT03345823) maintenance trials in patients …

es, be, us (code pays fourni par la source)

P0749 Association of endoscopic outcomes with long-term clinical improvements in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

E V Loftus, E Louis, P Bossuyt, Namita Joshi et autres

Abstract Background Endoscopic healing is an important treatment goal in Crohn’s disease (CD), in line with European Crohn’s and Colitis Organisation CD guidelines, as it is associated with improved long-term disease outcomes. We assessed the relationship between endoscopic healing and long-term clinical …

us, be, es (code pays fourni par la source)

Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study

Remo Panaccione, Jean-Frederic Colombel, Marla Dubinsky, Christopher Ma et autres

Background and Aims: Upadacitinib (UPA) is a Janus kinase inhibitor approved for moderately to severely active ulcerative colitis (UC). Patients may discontinue and then restart UPA treatment or require dose adjustment; however, the impact on overall efficacy of treatment interruption or dose …

ca, us, jp (code pays fourni par la source)